Achieving dendritic cell subset-specific targeting in vivo by site-directed conjugation of targeting antibodies to nanocarriers

The major challenge of nanocarrier-based anti-cancer vaccination approaches is the targeted delivery antigens and immunostimulatory agents to cells interest, such as specific subtypes dendritic (DCs), in order induce robust antigen-specific anti-tumor responses. An undirected cell body distribution nanocarriers can lead an unwanted other immune types like macrophages reducing vaccine efficacy. often-used approach overcome this issue surface functionalization with targeting moieties, antibodies, mediating type-specific interactions. Numerous studies could successfully prove efficiency antibody-conjugated carrier systems vitro, however, most them failed when DCs vivo that partly due reticuloendothelial system unspecifically clearing from blood stream via Fc receptor ligation. Therefore, study shows a strategy site-specifically attach antibodies orientated direction onto nanocarrier surface. Different DC-targeting anti-CD11c, anti-CLEC9A, anti-DEC205, anti-XCR1, were conjugated at their regions. Anti-mouse CD11c specifically accumulated organ (spleen) over time. Additionally, against CLEC9A proved direct DC subtype, conventional type 1. In conclusion, site-directed antibody conjugation essential avoid unspecific uptake by non-target while achieving antibody-specific subsets. This novel technique paves way for development antibody-functionalized DC-based field cancer immunotherapy.